What did @fryedmontgomery actually say?
Monty Fry describes living with Kallmann syndrome, a genetic condition causing absent or incomplete puberty due to GnRH deficiency, and explains how switching from estrogen-based HRT to testosterone one year ago transformed their health and wellbeing. They claim testosterone improved bone density, triggered olfactory development (their nose "growing"), and partially restored libido. They also note that infertility, a common concern for trans people starting HRT, was already a pre-existing reality for most Kallmann cases. The video is personal testimony, not a medical recommendation, and Fry is careful to frame their experience in first-person throughout.
Does the science back this up?
Mostly, yes. The core claims about Kallmann syndrome and testosterone therapy hold up reasonably well against published research. The infertility claim is accurate for the majority of untreated cases, and the bone density claim has solid support. The nose claim is the most surprising, but it is not implausible.
Kallmann syndrome results from mutations affecting GnRH neuronal migration, often co-occurring with anosmia or hyposmia due to olfactory bulb hypoplasia (Boehm et al., 2015, Nature Reviews Endocrinology). Testosterone therapy in hypogonadal individuals, regardless of sex assigned at birth, is well-documented to improve bone mineral density. A 2019 meta-analysis by Nokoff et al. in Journal of Clinical Endocrinology and Metabolism found significant BMD gains in transgender men on testosterone. Libido effects of testosterone are also well-established. The olfactory improvement claim is where things get more speculative. Some case reports document partial olfactory recovery in Kallmann patients on GnRH or gonadotropin therapy, but testosterone alone improving olfaction is not strongly documented. It is possible Fry is experiencing a secondary effect, or attributing natural variation to testosterone, but it is not an unreasonable observation for a single case.
What did they get wrong (or right)?
The infertility framing is accurate and actually more nuanced than most HRT content online. Fry is right that the majority of Kallmann cases with absent puberty present with infertility. A 2021 review by Boehm in Best Practice and Research Clinical Endocrinology confirms that spontaneous fertility is rare without gonadotropin replacement therapy specifically. Credit where it is due: they did not overstate this or claim testosterone caused it.
What they got slightly wrong, or at least imprecise, is the phrase "formoneless self." People with untreated Kallmann syndrome are not literally hormone-free. They have severely reduced sex hormone levels but still produce cortisol, thyroid hormones, and other endogenous hormones. Going off sex hormone replacement entirely does create real health risks, particularly accelerated bone loss and cardiovascular effects, which Fry acknowledges implicitly by calling it "never sustainable or healthy." That part is correct. The framing is poetic but not quite biologically precise.
The mispronunciation of "Kallmann" as "common syndrome" throughout is clearly a transcription artifact, not a factual error by Fry.
What should you actually know?
If you have Kallmann syndrome or another form of hypogonadotropic hypogonadism, the choice of sex hormone replacement matters and is genuinely a medical decision, not just a lifestyle one. Bone density, cardiovascular risk, and metabolic markers all respond differently to testosterone versus estradiol replacement, and "what feels right" is a valid data point in shared decision-making, not a replacement for lab monitoring.
Fry's experience of feeling better on testosterone is consistent with what some clinicians describe in intersex and trans patients who switch hormone regimens, but individual biochemistry varies considerably. Testosterone therapy carries its own risks including erythrocytosis, lipid changes, and effects on liver enzymes that require regular monitoring. None of that invalidates Fry's experience. It just means that anyone inspired by this video to consider switching hormones should do so with a clinician who understands both hypogonadism and gender-affirming care, not based on a single personal account, however compelling.
One more thing worth saying plainly: Fry is not practicing medicine here. They explicitly describe themselves as "a case study." That is an honest framing. The video does not tell anyone what to do, and that matters.